Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lenabasum

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented
    Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented

    21 Oct 2020

    // PRESS RELEASE

    https://ir.corbuspharma.com/press-releases/detail/344

    PRESS RELEASE
    21 Oct 2020
    Share Share
    Corbus ’ Second Quarter 2020 Earnings Conference Call and Webcast
    Corbus ’ Second Quarter 2020 Earnings Conference Call and Webcast

    05 Aug 2020

    // PRESS RELEASE

    https://ir.corbuspharma.com/press-releases/detail/339

    PRESS RELEASE
    05 Aug 2020
    Share Share
    Corbus Announces Publication of Phase 2b Cystic Fibrosis Study
    Corbus Announces Publication of Phase 2b Cystic Fibrosis Study

    01 Jun 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/06/01/2041453/0/en/Corbus-Pharmaceuticals-Announces-Publication-of-Phase-2b-Cystic-Fibrosis-Study-Patient-Demographics-and-Baseline-Disease-Characteristics-in-the-Journal-of-Cystic-Fibrosis.html

    GLOBENEWSWIRE
    01 Jun 2020
    Share Share
    Corbus Pharma Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum
    Corbus Pharma Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum

    27 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/27/2039357/0/en/Corbus-Pharmaceuticals-Reports-Last-Subject-Visit-in-RESOLVE-1-Phase-3-Study-of-Lenabasum-for-Treatment-of-Systemic-Sclerosis.html

    GLOBENEWSWIRE
    27 May 2020
    Share Share